在加勒比海西班牙裔人群中实施药物基因组驱动的算法指导抗血小板治疗:非随机的前性队列研究
Héctor Nuñez-Medina1, Mariangeli Monero2, Lorna M Torres1
1Division of Cardiovascular Medicine, University of Puerto Rico - Medical Sciences Campus, School of Medicine, San Juan, Puerto Rico, United States.
medRxiv : the preprint server for health sciences
|December 18, 2023
概括
基因型指导的抗血小板治疗减少了冠状动脉支架后加勒比海西班牙裔患者的心血管事件. 这种使用临床决策支持算法的药物基因组方法与标准护理相比,改善了结果.
科学领域:
- 药物基因组学 药物基因组学
- 心血管医学 心血管医学
- 临床决策支持系统 临床决策支持系统
背景情况:
- 经过皮肤冠状动脉干预 (PCI) 耐克克洛皮多格雷尔的患者面临重大心血管和脑血管不良事件 (MACCE) 的风险增加.
- 加勒比海西班牙裔人口在药物基因组 (PGx) 引导的实施研究中代表性不足.
- 这项研究研究了基因型导向抗血小板疗法在这个特定的人口.
研究的目的:
- 评估基因型引导的临床决策支持 (CDS) 算法是否可以减少PCI后缺血事件.
- 为了评估加勒比海西班牙裔患者使用PGx引导治疗的治疗结果的改善.
- 在多样化的群体中展示PGx驱动的CDS算法的临床实用性.
主要方法:
- 包括血小板功能测试 (PRU),CYP2C19*2和PON1 rs662基因型,以及来自8个机构的临床数据.
- 与基因型指导组 (每个150名患者) 进行标准护理 (SoC) 的比较.
- 利用CDS算法对高风险患者进行风险分层和提卡格勒勒推;使用Kaplan-Meier和Cox回归分析结果.
主要成果:
- 该研究包括300名患者 (平均年龄67岁,48%为女性,59%患有2型糖尿病).
- 在高风险患者中,基因型导向抗血小板疗法表现出对SoC的优越性.
- 在基因型导向组中观察到,静脉动脉瘤事件的发病率降低了.
结论:
- 药物基因学驱动的CDS算法在临床上证明在减少MACCEs方面是有用的.
- 外部验证证实了该算法在PCI后的加勒比海西班牙裔患者中对克洛皮多格雷尔的疗效.
- 基因型导向治疗为优化特定人群抗血小板治疗提供了一个有希望的策略.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
526
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
526
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
526
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
526
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
174
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
174
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
708
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
708
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K


